OMA Guidelines Bundle

Obesity-Related Diseases 2026

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1544298

Contents of this Issue

Navigation

Page 41 of 45

42 Management Obesity and Polycystic Ovary Syndrome   ➤ Diagnosis can be established based on varying sets of criteria; however, most experts recommend using the Rotterdam criteria and excluding other conditions that can present with similar clinical findings.   ➤ The presence of two of the following three criteria: oligo- or anovulation, clinical and/ or biochemical signs of hyperandrogenism, and polycystic ovarian morphology on ultrasound, suggests PCOS.   ➤ To confirm the diagnosis of PCOS, exclude thyroid disease, hyperprolactinemia, and congenital adrenal hyperplasia with the following tests: serum thyroid-stimulating hormone (TSH), prolactin, and 17-hydroxyprogesterone (collected before 8:30 AM during the follicular phase).   ➤ Recommend lifestyle changes that improve central adiposity and address both reproductive and metabolic dysfunction.   ➤ No specific dietary intervention is recommended: Tailor the plan to achieve nutritional goals while considering patient preferences, psychological factors, and sociocultural factors.   ➤ Behavioral strategies may include self-monitoring, goal setting, stimulus control, problem-solving, and relapse prevention.   ➤ Address psychological factors such as body image issues, eating disorders, and the need for non-stigmatizing, patient-centered communication.   ➤ Avoid sedentary behavior by engaging in regular physical activity, with no specific modality preferred.   ➤ Follow the duration and intensity guidelines for general health and weight management. For the management of menstrual abnormalities, hirsutism, or acne, first-line therapy is combined hormonal contraception.   ➤ If hirsutism and/or acne are not well controlled after six months of combined estrogen-progestin oral contraceptives, consider adding spironolactone.   ➤ For women with PCOS who develop a metabolic disorder such as type 2 diabetes or dyslipidemia, recommend weight loss and direct therapy to address the metabolic disorder.   ➤ Consider metformin monotherapy in adults and adolescents with a BMI ≥25 kg/m².   ➤ For women with PCOS and anovulatory infertility who are pursuing pregnancy, recommend weight loss. If ovulation is not restored, refer to a gynecologist for ovulation induction.

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity-Related Diseases 2026